

# Do-Youn Oh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7977536/publications.pdf>

Version: 2024-02-01

241  
papers

14,264  
citations

57758

44  
h-index

24982

109  
g-index

244  
all docs

244  
docs citations

244  
times ranked

15439  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 111-121.	2.6	7
2	Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 541-553.	3.0	4
3	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
4	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366.	4.6	3
5	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618.	5.3	3
6	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247.	10.7	268
7	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS366-TPS366.	1.6	2
8	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 378-378.	1.6	146
9	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS621-TPS621.	1.6	0
10	Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS639-TPS639.	1.6	0
11	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS490-TPS490.	1.6	2
12	Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 439-439.	1.6	1
13	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 295-295.	1.6	17
14	Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022, 82, P2-13-07-P2-13-07.	0.9	12
15	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2022, 186, 631-643.	3.7	55
16	Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 522-532.	8.1	149
17	Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. <i>European Journal of Cancer</i> , 2022, 169, 188-197.	2.8	3
18	Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. <i>Cancer Medicine</i> , 2022, 11, 2550-2560.	2.8	25

#	ARTICLE	IF	CITATIONS
19	Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, 1, .		267
20	First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS3153-TPS3153.	1.6	2
21	PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an <i>FGFR2</i> gene fusion/rearrangement.. Journal of Clinical Oncology, 2022, 40, TPS4171-TPS4171.	1.6	6
22	Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer.. Journal of Clinical Oncology, 2022, 40, 4117-4117.	1.6	0
23	Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).. Journal of Clinical Oncology, 2022, 40, 4075-4075.	1.6	7
24	Identifying mechanisms of acquired immune escape from sequential, paired biopsies.. Journal of Clinical Oncology, 2022, 40, 2519-2519.	1.6	0
25	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. Journal of Clinical Oncology, 2022, 40, e14557-e14557.	1.6	0
26	Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.. Journal of Clinical Oncology, 2022, 40, TPS4186-TPS4186.	1.6	2
27	Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.. Journal of Clinical Oncology, 2022, 40, 4070-4070.	1.6	9
28	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GCJ): Preliminary results from a phase 1b/2 study.. Journal of Clinical Oncology, 2022, 40, 4032-4032.	1.6	6
29	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2022, 40, 3929-3939.	1.6	66
30	The prognostic role of soluble transforming growth factor- $\beta$ 2 and its correlation with soluble programmed death-ligand 1 in biliary tract cancer. Liver International, 2021, 41, 388-395.	3.9	4
31	Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. Clinical Cancer Research, 2021, 27, 713-718.	7.0	27
32	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 1-25.	2.6	29
33	Biliary tract cancer. Lancet, The, 2021, 397, 428-444.	13.7	429
34	A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. Clinical and Translational Science, 2021, 14, 990-1001.	3.1	0
35	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110428.	3.2	6
36	Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients. Cancer Research and Treatment, 2021, 53, 199-206.	3.0	9

#	ARTICLE	IF	CITATIONS
37	Open-label, phase II study of ladiratuzumab vedotin (LV) for castration-resistant prostate cancer (SGNLVA-005, trial-in-progress).. Journal of Clinical Oncology, 2021, 39, TPS185-TPS185.	1.6	1
38	WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer, 2021, 24, 1003-1020.	5.3	16
39	A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Investigational New Drugs, 2021, 39, 1324-1334.	2.6	2
40	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958.	5.3	61
41	Safety and activity of the TGF $\beta$ 2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. , 2021, 9, e002068.		95
42	Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer. Cancer Research and Treatment, 2021, 53, 471-479.	3.0	2
43	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Research and Treatment, 2021, 53, 291-300.	3.0	8
44	Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 7545-7554.	1.5	2
45	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2021, 39, 2565-2565.	1.6	4
46	Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut and Liver, 2021, 15, 466-475.	2.9	11
47	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3113-3113.	1.6	3
48	Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.. Journal of Clinical Oncology, 2021, 39, e14552-e14552.	1.6	0
49	DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.. Journal of Clinical Oncology, 2021, 39, TPS4166-TPS4166.	1.6	2
50	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. Journal of Clinical Oncology, 2021, 39, 4056-4056.	1.6	1
51	Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).. Journal of Clinical Oncology, 2021, 39, TPS4164-TPS4164.	1.6	1
52	The NHance <sup>®</sup> Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients. Biomedicines, 2021, 9, 665.	3.2	2
53	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632.	2.6	0
54	Abstract 2073: Co-Targeting PARP and ATR in biliary tract cancer. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
55	ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. <i>Cancer Letters</i> , 2021, 516, 38-47.	7.2	11
56	NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	62
57	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.1	194
58	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1468-1482.	10.7	30
59	Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy. <i>Scientific Reports</i> , 2021, 11, 296.	3.3	6
60	Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS256-TPS256.	1.6	1
61	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 164-164.	1.6	21
62	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 1096-1103.	3.0	9
63	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45
64	Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 33-39.	5.0	17
65	Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Clinical Infectious Diseases</i> , 2020, 71, 422-425.	5.8	32
66	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
67	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3185-3194.	1.6	233
68	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	5.1	288
69	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.7	620
70	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in patients with pretreated biliary tract cancer. , 2020, 8, e000564.		98
71	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	10.7	923
72	Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2020, 49, 393-407.	1.1	15

#	ARTICLE	IF	CITATIONS
73	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
74	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
75	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. <i>Cancer Science</i> , 2020, 111, 513-527.	3.9	32
76	Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3063-3063.	1.6	8
77	Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3603-3603.	1.6	23
78	Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4520-4520.	1.6	63
79	Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4597-4597.	1.6	8
80	ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3145-TPS3145.	1.6	6
81	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 477-477.	1.6	26
82	HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhialuronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 638-638.	1.6	51
83	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	1.6	3
84	Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 824-824.	1.6	16
85	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 ( <i>FGFR2</i> ) gene rearrangements (FOENIX-CCA3).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600.	1.6	34
86	Comparisons of Clinical Outcomes between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems. <i>Journal of Korean Medical Science</i> , 2020, 35, e117.	2.5	8
87	Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 149-166.	3.0	28
88	Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 945-956.	3.0	14
89	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1178-1187.	3.0	12
90	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3054-3054.	1.6	1



#	ARTICLE	IF	CITATIONS
91	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. Journal of Clinical Oncology, 2020, 38, e16800-e16800.	1.6	0
92	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 4540-4540.	1.6	6
93	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. Journal of Clinical Oncology, 2020, 38, 686-686.	1.6	0
94	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 712-712.	1.6	5
95	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. Journal of Clinical Oncology, 2020, 38, 750-750.	1.6	1
96	288â€¦A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. , 2020, , .		0
97	Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer. Scientific Reports, 2019, 9, 11131.	3.3	21
98	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. JAMA Network Open, 2019, 2, e198243.	5.9	25
99	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage lâ€™III breast cancer patients. British Journal of Cancer, 2019, 121, 230-236.	6.4	14
100	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. British Journal of Cancer, 2019, 121, 332-339.	6.4	19
101	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2019, 5, 1431.	7.1	417
102	ATM in DNA repair in cancer. , 2019, 203, 107391.		147
103	MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Letters, 2019, 465, 12-23.	7.2	21
104	Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987112.	3.2	27
105	Role of surgical resection in the era of <scp>FOLFIRINOX</scp> for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences, 2019, 26, 416-425.	2.6	33
106	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. Oncologist, 2019, 24, 1037-e636.	3.7	4
107	Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine, 2019, 381, 317-327.	27.0	1,521
108	Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients. Breast Cancer Research and Treatment, 2019, 176, 453-460.	2.5	9

#	ARTICLE	IF	CITATIONS
109	&lt;p&gt;Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 1717-1728.	2.0	13
110	Avelumab (antiâ€PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
111	GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. Gastric Cancer, 2019, 22, 932-940.	5.3	12
112	Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. ESMO Open, 2019, 4, e000575.	4.5	5
113	Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. Biomolecules, 2019, 9, 782.	4.0	7
114	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i>-paclitaxel plus gemcitabine (<i>nab</i>-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, 4000-4000.	1.6	125
115	Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.. Journal of Clinical Oncology, 2019, 37, 4034-4034.	1.6	3
116	Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.. Journal of Clinical Oncology, 2019, 37, 4117-4117.	1.6	63
117	A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) Î² receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 4124-4124.	1.6	24
118	Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.. Journal of Clinical Oncology, 2019, 37, TPS4155-TPS4155.	1.6	20
119	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. Journal of Clinical Oncology, 2019, 37, LBA4-LBA4.	1.6	11
120	Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.. Journal of Clinical Oncology, 2019, 37, 331-331.	1.6	9
121	Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).. Journal of Clinical Oncology, 2019, 37, 387-387.	1.6	90
122	MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)â€based combinations in gastrointestinal (GI) cancers.. Journal of Clinical Oncology, 2019, 37, TPS467-TPS467.	1.6	12
123	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring <i>FGFR2</i> gene rearrangements.. Journal of Clinical Oncology, 2019, 37, TPS468-TPS468.	1.6	6
124	Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer. Cancer Research and Treatment, 2019, 51, 886-900.	3.0	5
125	Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. Cancer Research and Treatment, 2019, 51, 1167-1179.	3.0	22
126	Halo 110-101: Early safety results of pegvorhialuronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) Â± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).. Journal of Clinical Oncology, 2019, 37, 408-408.	1.6	0



#	ARTICLE	IF	CITATIONS
127	Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 344-344.	1.6	1
128	The prognostic role of soluble transforming growth factor- $\beta$ 2 (sTGFB) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.. <i>Journal of Clinical Oncology</i> , 2019, 37, 257-257.	1.6	0
129	Predictive role of temporal changes in intratumoral metabolic heterogeneity during palliative chemotherapy in advanced pancreatic cancer patients: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 311-311.	1.6	0
130	A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 319-319.	1.6	1
131	Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4059-4059.	1.6	0
132	The prognostic role of soluble transforming growth factor- $\beta$ 2 related with soluble programmed death-ligand 1 in biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4094-4094.	1.6	2
133	Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer. <i>Annals of Surgery</i> , 2018, 268, 215-222.	4.2	497
134	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 252.	2.6	7
135	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	1.6	524
136	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018, 430, 123-132.	7.2	52
137	Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4079-4079.	1.6	1
138	TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4143-TPS4143.	1.6	3
139	A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 217-217.	1.6	28
140	The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 288-288.	1.6	1
141	Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 470-470.	1.6	16
142	MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS530-TPS530.	1.6	6
143	HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS543-TPS543.	1.6	1
144	Prognostic implication of soluble programmed death-ligand 1 (sPDL1) and its dynamic changes during FOLFIRINOX chemotherapy in unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 306-306.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 164-174.	5.3	13
146	Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 254-262.	5.3	51
147	Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. <i>Psycho-Oncology</i> , 2017, 26, 1810-1817.	2.3	9
148	Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1145-1154.	4.1	45
149	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1197-1207.	2.3	27
150	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
151	Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. <i>Cancer Letters</i> , 2017, 411, 162-170.	7.2	10
152	Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. <i>Journal of Nuclear Medicine</i> , 2017, 58, 899-904.	5.0	20
153	Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel. <i>Oncotarget</i> , 2017, 8, 93117-93130.	1.8	28
154	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. <i>Cancer Research and Treatment</i> , 2017, 49, 851-868.	3.0	50
155	Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. <i>Oncotarget</i> , 2017, 8, 2329-2341.	1.8	50
156	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5013-5030.	2.0	8
157	A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 294-294.	1.6	3
158	Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 454-463.	3.0	1
159	Prospective evaluation of the clinical implications of the tumor metabolism and chemotherapy-related changes in advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 261-261.	1.6	1
160	Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 416-416.	1.6	1
161	Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 460-460.	1.6	0
162	Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 454-454.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Therapeutic implication of HER2 in advanced biliary tract cancer. <i>Oncotarget</i> , 2016, 7, 58007-58021.	1.8	63
164	Src as a Therapeutic Target in Biliary Tract Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1515-1524.	4.1	10
165	Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515.	2.6	11
166	TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. <i>British Journal of Cancer</i> , 2016, 115, 1201-1205.	6.4	19
167	Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. <i>Nutrition and Cancer</i> , 2016, 68, 750-755.	2.0	0
168	Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. <i>European Radiology</i> , 2016, 26, 2771-2778.	4.5	31
169	Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 115, 164-171.	6.4	43
170	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 233-241.	2.5	10
171	Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 707-714.	2.5	8
172	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 1095-1103.	5.3	33
173	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2016, 387, 968-977.	13.7	962
174	Pertuzumab in gastrointestinal cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 243-253.	3.1	12
175	A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograftim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. <i>Supportive Care in Cancer</i> , 2016, 24, 1709-1717.	2.2	19
176	Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. <i>Gastric Cancer</i> , 2016, 19, 421-430.	5.3	11
177	Weight loss at the first month of palliative chemotherapy predicts survival outcomes in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 597-606.	5.3	31
178	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3502-3502.	1.6	114
179	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4009-4009.	1.6	42
180	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4090-4090.	1.6	8

#	ARTICLE	IF	CITATIONS
181	Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. Journal of Clinical Oncology, 2016, 34, 517-517.	1.6	2
182	A phase 2, open-label, multicenter study of durvalumab (MEDI4736) ± tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.. Journal of Clinical Oncology, 2016, 34, TPS4150-TPS4150.	1.6	2
183	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline <i>BRCA1/2</i> mutation (g<i>BRCA</i>m).. Journal of Clinical Oncology, 2016, 34, TPS4152-TPS4152.	1.6	15
184	Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. Journal of Clinical Oncology, 2016, 34, 167-167.	1.6	27
185	Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.. Journal of Clinical Oncology, 2016, 34, 315-315.	1.6	7
186	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. Journal of Clinical Oncology, 2016, 34, 335-335.	1.6	42
187	More Accurate Prediction of Metastatic Pancreatic Cancer Patientsâ€™ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. PLoS ONE, 2016, 11, e0145692.	2.5	14
188	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. PLoS ONE, 2016, 11, e0151406.	2.5	15
189	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget, 2016, 7, 76604-76612.	1.8	93
190	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2016, 48, 28-36.	3.0	20
191	The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. Cancer Research and Treatment, 2016, 48, 171-179.	3.0	56
192	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. Cancer Research and Treatment, 2016, 48, 1045-1055.	3.0	10
193	Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. Cancer Research and Treatment, 2016, 48, 990-997.	3.0	15
194	Role of adjuvant chemoradiotherapy for duodenal cancer: An update of the experience at a single institution.. Journal of Clinical Oncology, 2016, 34, 370-370.	1.6	0
195	TTP or PFS as a surrogate endpoint in advanced hepatocellular carcinoma treated with systemic therapy.. Journal of Clinical Oncology, 2016, 34, 4075-4075.	1.6	0
196	Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2016, 34, e23268-e23268.	1.6	0
197	A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2521-2521.	1.6	1
198	Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. Clinical Epigenetics, 2015, 7, 63.	4.1	17

#	ARTICLE	IF	CITATIONS
199	Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. BMC Cancer, 2015, 15, 690.	2.6	9
200	Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer, 2015, 15, 721.	2.6	19
201	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Research, 2015, 17, 33.	5.0	138
202	Treatment for unresectable gastric cancer. Journal of the Korean Medical Association, 2015, 58, 209.	0.3	1
203	Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PLoS ONE, 2015, 10, e0139749.	2.5	183
204	Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Research and Treatment, 2015, 47, 343-361.	3.0	75
205	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. Oncologist, 2015, 20, 926-933.	3.7	15
206	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. Clinical Cancer Research, 2015, 21, 2520-2529.	7.0	59
207	Quantitative measurement of HER2 levels by multiplexed mass spectrometry to predict survival in gastric cancer patients treated with trastuzumab.. Journal of Clinical Oncology, 2015, 33, 4050-4050.	1.6	1
208	Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 523-523.	1.6	3
209	Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2015, 33, 276-276.	1.6	2
210	Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. Cancer Research and Treatment, 2015, 47, 687-696.	3.0	11
211	Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment, 2015, 47, 607-615.	3.0	93
212	Adjuvant treatment patterns and clinical outcomes in patients with curative resected ampulla of Vater cancer.. Journal of Clinical Oncology, 2015, 33, 415-415.	1.6	1
213	Change of skeletal muscle index during the chemotherapy as a prognostic factor of survival in pancreatic cancer patients receiving palliative chemotherapy.. Journal of Clinical Oncology, 2015, 33, 363-363.	1.6	0
214	Weight loss at the first month of palliative chemotherapy to predict survival outcomes in patients with advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 83-83.	1.6	0
215	Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2015, 33, e15197-e15197.	1.6	0
216	Measurement of soluble Programmed Death-Ligand 1 (soluble PD-L1) to predict survival in biliary tract cancer patients treated with chemotherapy.. Journal of Clinical Oncology, 2015, 33, 11094-11094.	1.6	0



#	ARTICLE	IF	CITATIONS
217	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. American Journal of Cancer Research, 2015, 5, 3376-88.	1.4	6
218	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science, 2014, 29, 1094.	2.5	22
219	The Impact of Body Mass Index Dynamics on Survival of Patients With Advanced Pancreatic Cancer Receiving Chemotherapy. Journal of Pain and Symptom Management, 2014, 48, 13-25.	1.2	17
220	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 2014, 50, 2072-2081.	2.8	283
221	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2014, 32, 1038-1038.	1.6	0
222	Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Research, 2014, 34, 4275-80.	1.1	7
223	Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2013, 45, 325-333.	3.0	49
224	Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer, 2012, 118, 6162-6170.	4.1	83
225	A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational New Drugs, 2012, 30, 1164-1174.	2.6	19
226	Evaluation of the willingness to pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 282-291.	1.1	18
227	Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. Journal of Neuro-Oncology, 2012, 106, 303-313.	2.9	64
228	A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3076-3076.	1.6	6
229	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	1.6	29
230	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, LBA1-LBA1.	1.6	34
231	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. Journal of Clinical Oncology, 2012, 30, 98-98.	1.6	2
232	Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in previously treated advanced hepatocellular carcinoma.. Journal of Clinical Oncology, 2012, 30, 269-269.	1.6	2
233	Genetic polymorphisms and ethnic difference in outcome of adjuvant FOLFOX chemotherapy in Korean patients with colon cancer.. Journal of Clinical Oncology, 2012, 30, 623-623.	1.6	0
234	Methylations of NEUROG1, p16, and MLH1 and recurrence following adjuvant FOLFOX in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3624-3624.	1.6	0



#	ARTICLE	IF	CITATIONS
235	Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2012, 30, e14617-e14617.	1.6	0
236	Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. Diagnostic Molecular Pathology, 2011, 20, 94-100.	2.1	31
237	Public Awareness of Gastric Cancer Risk Factors and Disease Screening in a High Risk Region: A Population-Based Study. Cancer Research and Treatment, 2009, 41, 59.	3.0	34
238	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer, 2009, 65, 80-84.	2.0	118
239	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Letters, 2008, 272, 296-306.	7.2	111
240	TGF- $\beta$ 2 Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells. Cancer Research and Treatment, 1970, 47, 101-109.	3.0	13
241	A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene, 0, , .	5.9	3